Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: A novel therapy for Parkinson's disease

Neuron

Volumn 37, Issue 6, 2003, Pages 899-909

  Kaur, Deepinder ^a   Yantiri, Ferda ^b   Rajagopalan, Subramanian ^a   Kumar, Jyothi ^a   Mo, Jun Qin ^b   Boonplueang, Rapee ^b   Viswanath, Veena ^b   Jacobs, Russell ^c   Yang, Lichuan ^d   Beal, M Flint ^d   DiMonte, Dino ^e   Volitaskis, Irene ^f   Ellerby, Lisa ^a   Cherny, Robert A ^f   Bush, Ashley I ^f,g   Andersen, Julie K ^a,b  

^a BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e PARKINSON S INSTITUTE   (United States)

^f UNIVERSITY OF MELBOURNE   (Australia)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CHELATING AGENT; CLIOQUINOL; FERRITIN; IRON; IRON BINDING PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHELATION THERAPY; CONTROLLED STUDY; DISEASE PREDISPOSITION; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG TOLERABILITY; GENE EXPRESSION; IRON CHELATION; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; TRANSGENE; TREATMENT OUTCOME;

EID: 0242684415     PISSN: 08966273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0896-6273(03)00126-0     Document Type: Article

References (89)

1. Adams J.D. Jr., Odunze I.N. Oxygen free radicals and Parkinson's disease. Free Radic. Biol. Med. 10:1991;161-169.
2. Agrawal R., Sharma P.K., Rao G.S. Release of iron from ferritin by metabolites of benzene and superoxide radical generating agents. Toxicology. 168:2001;223-230.
3. Ali S.F., LeBel C.P., Bondy S.C. Reactive oxygen species formation as a biomarker of methylmercury and trimethyltin neurotoxicity. Neurotoxicology. 13:1992;637-648.
4. Andersen, J.K. (2001). Do alterations in glutathione and iron levels contribute to pathology associated with Parkinson's disease? In Ageing Vulnerability: Causes and Interventions, Novartis Foundation Symposium, Volume 235 (New York: John Wiley and Sons, Inc.), pp. 11-25.
5. Andersen J.K., Frim D.M., Isacson O., Beal M.F., Breakefield X.O. Elevation of neuronal MAO-B activity in a transgenic mouse model does not increase sensitivity to the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Brain Res. 656:1994;108-114.
6. Banerjee S.A., Hoppe P., Brillliant M., Chikaraishi D.M. 5′ flanking sequences of the rat tyrosine hydroxylase gene target accurate tissue-specific, developmental, and transsynaptic expression in transgenic mice. J. Neurosci. 12:1992;4460-4467.
7. Bartzokis G., Beckson M., Hance D.B., Marx P., Foster J.A., Marder S.R. MR evaluation of age-related increase of brain iron in young adult and older normal males. Magn. Reson. Imaging. 15:1997;29-35.
8. Baumgartner G., Gawel M.J., Kaeser H.E., Pallis C.A., Rose F.C., Schaumburg H.H., Thomas P.K., Wadia N.H. Neurotoxicity of halogenated hydroxyquinolines. clinical analysis of cases reported outside Japan J. Neurol. Neurosurg. Psychiatry. 42:1979;1073-1083.
9. Beal F. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann. Neurol. 31:1992;119-130.
10. Beal M.F. Experimental models of Parkinson's disease. Nat. Rev. Neurosci. 2:2001;325-334.
11. Beard J.L., Connor J.D., Jones B.C. Brain iron. location and function Prog. Food Nutr. Sci. 17:1993;183-221.
12. Benkovic S.A., Connor J.R. Ferritin, transferrin, and iron in selected regions of the adult and aged rat brain. J. Comp. Neurol. 338:1993;97-113.
13. Berg D., Gerlach M., Youdim M.B., Double K.L., Zecca L., Riederer P., Becker G. Brain iron pathways and their relevance to Parkinson's disease. J. Neurochem. 79:2001;225-236.
14. Betarbet R., Sherer T.B., Greenamyre J.T. Animal models of Parkinson's disease. Bioessays. 24:2002;308-318.
15. Bush A.I. Metals and neuroscience. Curr. Opin. Chem. Biol. 4:2000;184-191.
16. Cassarino D.S., Parks J.K., Parker W.D. Jr., Bennett J.P. Jr. The parkinsonian neurotoxin MPP+ opens the mitochondrial permeability transition pore and releases cytochrome c in isolated mitochondria via an oxidative mechanism. Biochim. Biophys. Acta. 1453:1999;49-62.
17. Castellani R.J., Siedlak S.L., Perry G., Smith M.A. Sequestration of iron by Lewy bodies in Parkinson's disease. Acta Neuropathol. (Berl.). 100:2000;111-114.
18. Caughman S.W., Hentze M.W., Rouault T.A., Hartford J.B., Klausner R.D. The iron-responsive element is the single element responsible for iron-dependent translational regulation of ferritin biosynthesis. Evidence for function as the binding site for a translational repressor. J. Biol. Chem. 263:1988;19048-19052.
19. Cheepsunthorn P., Palmer C., Connor J.R. Cellular distribution of ferritin subunits in postnatal rat brain. J. Comp. Neurol. 400:1998;73-86.
20. Cherny R.A., Atwood C.S., Xilinas M.E., Gray D.N., Jones W.D., McLean C.A., Barnham K.J., Volitakis I., Fraser F.W., Kim Y.et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron. 30:2001;665-676.
21. Chiueh C.C., Rauhala P. Free radicals and MPTP-induced selective destruction of substantia nigra compacta neurons. Adv. Pharmacol. 42:1998;796-800.
22. Christen Y. Oxidative stress and Alzheimer disease. Am. J. Clin. Nutr. 71:2000;621S-629S.
23. Clifford Rose F., Gawel M. Clioquinol neurotoxicity. an overview Acta Neurol. Scand. Suppl. 100:1984;137-145.
24. Connor J.R., Snyder B.S., Beard J.L., Fine R.E., Mufson E.J. Regional distribution of iron and iron-regulatory proteins in the brain in aging and Alzheimer's disease. J. Neurosci. Res. 31:1992;327-335.
25. Connor J.R., Boeshore K.L., Benkovic S.A., Menzies S.L. Isoforms of ferritin have a specific cellular distribution in the brain. J. Neurosci. Res. 37:1994;461-465.
26. Connor J.R., Snyder B.S., Arosio P., Loeffler D.A., LeWitt P. A quantitative analysis of isoferritins in select regions of aged, Parkinsonian, and Alzheimer's diseased brains. J. Neurochem. 65:1995;717-724.
27. Connor J.R., Menzies S.L., Burdo J.R., Boyer P.J. Iron and iron management proteins in neurobiology. Pediatr. Neurol. 25:2001;118-129.
28. Cozzi A., Corsi B., Levi S., Santambrogio P., Albertini A., Arosio P. Overexpression of wild type and mutated human ferritin H-chain in HeLa cells. in vivo role of ferritin ferroxidase activity J. Biol. Chem. 275:2000;25122-25129.
29. Curtis A.R., Fey C., Morris C.M., Bindoff L.A., Ince P.G., Chinnery P.F., Coulthard A., Jackson M.J., Jackson A.P., McHale D.P.et al. Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nat. Genet. 28:2001;350-354.
30. +) levels, ascorbic acid oxidation and glutathione levels in the striatal synaptosomes of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated rat. Neurosci. Lett. 161:1993;121-123.
31. Dexter D.T., Wells F.R., Agid F., Agid Y., Lees A.J., Jenner P., Marsden C.D. Increased nigral iron content in postmortem parkinsonian brain. Lancet. 21:1987;1219-1220.
32. Dexter D.T., Wells F.R., Lees A.J., Agid F., Agid Y., Jenner P., Marsden C.D. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J. Neurochem. 52:1989;1830-1836.
33. Dexter D.T., Carayon A., Javoy-Agid F., Agid Y., Wells F.R., Daniel S.E., Lees A.J., Jenner P., Marsden C.D. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain. 114:1991;1953-1975.
34. Double K.L., Maywald M., Schmittel M., Reiderer P., Gerlach M. In vitro studies of ferritin iron release and neurotoxicity. J. Neurochem. 70:1998;2492-2499.
35. Du Y., Ma Z., Lin S., Dodel R.C., Gao F., Bales K.R., Triarhou L.C., Chernet E., Perry K.W., Nelson D.L.et al. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc. Natl. Acad. Sci. USA. 98:2001;14669-14674.
36. Gassen M., Youdim M.B.H. The potential role of iron chelators in the treatment of Parkinson's disease and related neurological disorders. Pharmacol. Toxicol. 80:1997;159-166.
37. Gerlach M., Ben-Shachar D., Riederer P., Youdim M.B. Altered brain metabolism of iron as a cause of neurodegenerative diseases? J. Neurochem. 63:1994;793-807.
38. Gilissen E.P., Ghosh P., Jacobs R.E., Allman J.M. Topographical localization of iron in brains of the aged fat-tailed dwarf lemur (Cheirogaleus medius) and gray lesser mouse lemur (Microcebus murinus). Am. J. Primatol. 45:1998;291-299.
39. Gitlin J.D. Aceruloplasminemia. Pediatr. Res. 44:1998;271-276.
40. Glinka Y., Gassen M., Youdim M.B.H. The role of iron in Parkinson's disease. Connor J.R. Metals and Oxidative Damage in Neurological Disorders. 1996;Plenium Publishing Corp, Boston, MA. 1-12.pp.
41. Griffith O. Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine. Anal. Biochem. 106:1980;207-212.
42. Griffiths P.D., Dobson B.R., Jones G.R., Clarke D.T. Iron in the basal ganglia in Parkinson's disease. An in vitro study using extended X-ray absorption fine structure and cryo-electron microscopy. Brain. 122:1999;667-673.
43. Gutteridge J.M.C. Iron and oxygen radicals in brain. Ann. Neurol. 32:1992;S16-S21.
44. Han J., Day J.R., Thomson K., Connor J.R., Beard J.L. Iron deficiency alters H- and L-ferritin expression in rat brain. Cell Mol. Biol. 46:2000;517-528.
45. Harrison P.M., Arosio P. The ferritins. molecular properties, iron storage function and cellular regulation Biochim. Biophys. Acta. 1275:1996;161-203.
46. Hentze M.W., Keim S., Papadopoulos P., O'Brien S., Modi W., Drysdale J., Leonard W.J., Harford J.B., Klausner R.D. Cloning, characterization, expression, and chromosomal localization of a human ferritin heavy-chain gene. Proc. Natl. Acad. Sci. USA. 83:1986;7226-7230.
47. Hill J.M., Switzer R.C. The regional distribution and cellular localization of iron in the rat brain. Neuroscience. 11:1984;595-603.
48. Huang X., Cuajungco M.P., Atwood C.S., Hartshorn M.A., Tyndall J.D., Hanson G.R., Stokes K.C., Leopold M., Multhaup G., Goldstein L.E.et al. Cu(II) potentiation of Alzheimer α-beta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. J. Biol. Chem. 274:1999;37111-37116.
49. Hung H.-C., Lee E.H. MPTP produces differential oxidative stress and antioxidative responses in the nigrostriatal and mesolimbic dopaminergic pathways. Free Radic. Biol. Med. 24:1998;76-84.
50. Janetzky B., Reichmann H., Youdim M.B., Reiderer P. Iron and oxidative damage in neurodegenerative disease. Beal F., Howell N., Bodis-Wollner I. Mitochondria and Free Radicals in Neurodegenerative Diseases. 1997;Wiley-Liss Inc, New York. 407-421.pp.
51. Jellinger K. The role of iron in neurodegeneration. prospects for pharmacotherapy of Parkinson's disease Drugs Aging. 14:1999;115-140.
52. Jellinger K., Paulus W., Grundke-Iqbal I., Riederer P., Youdim M.B. Brain iron and ferritin in Parkinson's and Alzheimer's diseases. J. Neural Transm. Park. Dis. Dement. Sect. 2:1990;327-340.
53. Jenner P., Schapira A.H., Marsden C.D. New insights into the cause of Parkinson's disease. Neurology. 42:1992;2241-2250.
54. Kato J., Fujikawa K., Kanda M., Fukuda N., Sasaki K., Takayama T., Kobune M., Takada K., Takimoto R., Hamada H.et al. A mutation in the iron-responsive element of H-ferritin mRNA causing autosomal dominant iron overload. Am. J. Hum. Genet. 69:2001;191-197.
55. Kidani Y., Naga S., Koike H. Mass spectrometry of 5-chloro-7-iodo-8-quinol metal chelates. Jap. Analyst. 23:1974;1375-1378.
56. Klivenyi P., Andreassen O.A., Ferrante R.J., Dedeoglu A., Mueller G., Lancelot E., Bogdanov M., Andersen J.K., Jiang D., Beal M.F. Mice deficient in cellular glutathione peroxidase show increased vulnerability to malonate, 3-nitropropionic acid, and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. J. Neurosci. 20:2000;1-7.
57. Lan J., Jiang D.H. Excessive iron accumulation in the brain. a possible potential risk of neurodegeneration and Parkinson's disease J. Neural Transm. 104:1997;649-660.
58. Mann V.M., Cooper J.M., Danie S.E., Srai K., Jenner P., Marsden C.D., Schapira A.H. Complex I, iron, and ferritin in Parkinson's disease substantia nigra. Ann. Neurol. 36:1994;876-881.
59. Marciani M.G., Cianciulli P., Stefani N., Stefanini F., Peroni L., Sabbadini M., Maschio M., Trua G., Papa G. Toxic effects of high-dose deferoxamine treatment in patients with iron overload. an electrophysiological study of cerebral and visual function Haematologica. 76:1991;131-134.
60. th International Conference on Alzheimer's Disease and Related Disorders, Stockholm, Sweden, July 20-25, 2002.
61. Meade T.W. Subacute myelo-optic neuropathy and clioquinol. An epidemiological case-history for diagnosis. Br. J. Prev. Soc. Med. 29:1975;157-169.
62. Melov S. And C is for clioquinol - the AβCs of Alzheimer's disease. Trends Neurosci. 25:2002;121-123.
63. Moos T., Trinder D., Morgan E.H. Cellular distribution of ferric iron, ferritin, transferrin and divalent metal transporter 1 (DMT1) in substantia nigra and basal ganglia of normal and beta 2-microglobulin deficient mouse brain. Cell Mol. Biol. 46:2000;549-561.
64. Morgan T.E., Xie Z., Goldsmith S., Yoshida T., Lanzrein A.S., Stone D., Rozovsky I., Perry G., Smith M.A., Finch C.E. The mosaic of brain glial hyperactivity during normal ageing and its attenuation by food restriction. Neuroscience. 89:1999;687-699.
65. Nakae K., Yamamoto S., Shigematsu I., Kono R. Relation between subacute myelo-optic neuropathy (S.M.O.N.) and clioquinol. nationwide survey Lancet. 1:1973;171-173.
66. Nicholson D.W., Ali A., Thornberry N.A., Vaillancourt J.P., Ding C.K., Gallant M., Gareau Y., Griffin P.R., Labelle M., Lazebnik Y.A.et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature. 376:1995;37-43.
67. Orino K., Lehman L., Tsuji Y., Ayaki H., Torti S.V., Torti F.M. Ferritin and the response to oxidative stress. Biochem. J. 357:2001;241-247.
68. Perry T.L., Godin D.V., Hansen S. Parkinson's disease. a disorder due to nigral glutathione deficiency? Neurosci. Lett. 33:1982;305-310.
69. Porter J.B., Huehns E.R. The toxic effects of desferrioxamine. Baillieres Clin. Haematol. 2:1989;459-474.
70. Reiderer P., Sofic E., Rausch W.D., Schmidt B., Reynolds G., Jellinger K., Youdim M.B. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem. 52:1989;515-520.
71. Rucker P., Torti F.M., Torti S. Role of H and L subunits in mouse ferritin J. Biol. Chem. 52:1996;33352-33357.
72. Sedelis M., Schwarting R.K., Huston J.P. Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behav. Brain Res. 125:2001;109-125.
73. Sian J., Dexter D.T., Lees A., Daniel S., Agid Y., Javoy-Agid F., Jenner P., Marsden C.D. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann. Neurol. 36:1994;348-355.
74. Smith M.A., Harris P.L.R., Sayre L.M., Perry G. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc. Natl. Acad. Sci. USA. 94:1997;9866-9868.
75. Sofic E., Riederer P., Heinsen H., Beckmann H., Reynolds G.P., Hebenstreit G., Youdim M.B. Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J. Neural Transm. 74:1988;199-205.
76. Sofic E., Paulus W., Jellinger K., Riederer P., Youdim M.B. Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J. Neurochem. 56:1991;978-982.
77. Tateishi J. Subacute myelo-optico-neuropathy. clioquinol intoxication in humans and animals Neuropathology. Suppl. 20:2000;S20-S24.
78. Tetrud J.W., Langston J.W. MPTP-induced parkinsonism as a model for Parkinson's disease. Acta. Neuro. Scand. Suppl. 126:1989;35-40.
79. Thompson K.J., Shoham S., Connor J.R. Iron and neurodegenerative disorders. Brain Res. Bull. 55:2001;155-164.
80. Tsubaki T., Honma Y., Hoshi M. Neurological syndrome associated with clioquinol. Lancet. 1:1971;696-697.
81. Vila M., Jackson-Lewis V., Vukosavic S., Djaldetti R., Liberatore G., Offen D., Korsmeyer S.J., Przedborski S. Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Proc. Natl. Acad. Sci. USA. 98:2001;2837-2842.
82. West M.J. Regionally specific loss of neurons in the aging human hippocampus. Neurobiol. Aging. 14:1993;275-285.
83. Yantiri F., Andersen J.K. The role of iron in Parkinson disease and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity. IUBMB Life. 48:1999;1-3.
84. Yassin M.S., Ekblom J., Xilinas M., Gottfries C.G., Oreland L. Changes in uptake of vitamin B(12) and trace metals in brains of mice treated with clioquinol. J. Neurol. Sci. 173:2000;40-44.
85. Yong V.W., Perry T.L., Krisman A.A. Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients. Neurosci. Lett. 63:1986;56-60.
86. Yoshida S., Ektessabi A., Fujisawa S. XANES spectroscopy of a single neuron from a patient with Parkinson's disease. J. Synchrotron Radiat. 8:2001;998-1000.
87. Yoshimura S., Imai K., Saitoh Y., Yamaguchi H., Ohtaki S. The same chemicals induce different neurotoxicity when administered in high doses for short term or low doses for long term to rats and dogs. Mol. Chem. Neuropathol. 16:1992;59-84.
88. Youdim M.B., Ben-Shacher D., Reiderer P. The possible role of iron in the etiopathology of Parkinson's disease. Mov. Disord. 8:1993;1-12.
89. Zecca L., Gallorini M., Schunemann V., Trautwein A.X., Gerlach M., Riederer P., Vezzoni P., Tampellini D. Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages. consequences for iron storage and neurodegenerative processes J. Neurochem. 76:2001;1766-1773.